The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
October 2nd 2024
Positive trial results laid the groundwork for the designation.
Prime Data Suggest Specialty Drugs for HCV, RA Fail to Produce Savings
April 3rd 2013Prime Therapeutics' new studies, scheduled to be presented at AMCP, reveal that expected medical savings from the utilization of specialty drugs no longer offset the high cost of these therapies for the treatment of hepatitis C and rheumatoid arthritis.
Read More
MedCart Specialty Pharmacy: Preparing for the Next Advancements in Hepatitis C Therapy
December 18th 2012Therapy approvals significantly changed the landscape of treatment for hepatitis C and it is anticipated that the drugs in the treatment pipeline will mark significant advances in therapy as well.
Read More
The Specialty Pharmacy Pipeline: What's Next?
October 17th 2012In a session at the 2012 Academy of Managed Care Pharmacy Educational Conference, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within each medication class.
Read More
NIH Launches Free Database of Drugs Associated with Liver Injury
October 15th 2012A free source of evidence-based information for health care professionals and for researchers studying liver injury associated with prescription and over-the-counter drugs, herbals, and dietary supplements is now available from the National Institutes of Health.
Read More
FDA Approves First DNA Test to Help Manage CMV Infection in Organ Transplant Patients
July 9th 2012The FDA recently approved the first DNA test to help health care professionals gauge the progress of antiviral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy.
Read More
FDA Lists New Drug Interactions for Victrelis
February 9th 2012The FDA sent out a "Drug Safety Communication" from their Division of Drug Information on February 9, 2012, listing the important new drug interactions between Victrelis (boceprevir) and ritonavir-boosted HIV protease inhibitor drugs.
Read More